Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 16  |  Issue : 8  |  Page : 34--38

Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy


Kishore Singh1, Rubu Sunku2, Arun K Rathi1, Gaurav S Pradhan3 
1 Department of Radiation Oncology, Maulana Azad Medical College, Delhi, India
2 Department of Radiation Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam, India
3 Department of Radiodiagnosis, Maulana Azad Medical College, Delhi, India

Correspondence Address:
Rubu Sunku
Department of Radiation Oncology, Dr. B. Borooah Cancer Institute, Guwahati, Assam
India

Purpose: The purpose of this study was to correlate treatment response with tumor blood perfusion in patient of advanced head-and-neck cancer undergoing neoadjuvant chemotherapy. Materials and Methods: A total of 40 patients of advanced head-and-neck cancer, who were planned for neoadjuvant chemotherapy, were included in the study. All patients underwent diagnostic computed tomography (CT) with perfusion study for staging and quantitative measurement of tumor volume as well as perfusion parameters (including tumor blood volume, blood flow, permeability, and time to peak enhancement), at baseline and after completion of neoadjuvant chemotherapy. Total 3 cycles of neoadjuvant chemotherapy with paclitaxel, cisplatin, and 5 fluorouracil were given. Tumor response was evaluated in terms of change in tumor volume and correlated with perfusion parameters. Results: Out of 40 patients, 22 patients had more than 50% reduction in tumor volume, who were grouped as responder and remaining 18 patients had <50% decrease in tumor volume, grouped as nonresponder. Both the groups were similar in terms of age, gender, performance status, stage, nodal status, or addiction. Baseline CT scan shows a significant difference in tumor blood flow (P = 0.048) and marginal difference in time to peak enhancement (P = 0.058) in two groups. However, there is no difference in tumor blood volume (P = 0.32) and permeability surface area (P = 0.07). Conclusions: Evaluation of tumor blood flow by perfusion CT is helpful in predicting chemotherapy outcome and deciding appropriate treatment modality, but further evaluation with more number of patients is required for validating the predictive role of each perfusion parameters.


How to cite this article:
Singh K, Sunku R, Rathi AK, Pradhan GS. Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy.J Can Res Ther 2020;16:34-38


How to cite this URL:
Singh K, Sunku R, Rathi AK, Pradhan GS. Predicting outcome of advanced head-and-neck cancer by measuring tumor blood perfusion in patients receiving neoadjuvant chemotherapy. J Can Res Ther [serial online] 2020 [cited 2021 Sep 22 ];16:34-38
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=8;spage=34;epage=38;aulast=Singh;type=0